In 2018, funding for preventive AIDS vaccines R&D decreased by a marginal 0.3 percent or US$2.7 million from the previous year, to a total of US$842 million. The public sector made up 78 percent of overall investment, at US$657.8 million, with the philanthropic and commercial sectors contributing 15.5 percent and 6.4 percent, respectively.
At US$626 million or 95 percent of all public sector funding, the US remained the largest donor of preventive vaccine research globally. US public sector funding increased by 0.2 percent from 2017 levels, to US$626 million, an uptick bolstered by the eight percent increase in funding from the MHRP.
For more, read the full report.